NASDAQ · CALC

CalciMedica, Inc.

Healthcare · Biotechnology

$1.86▼ 3.13% ($0.06)at close

As of 4:00 PM ET

52-week

$1.86$36.00

Market cap

$5.86M

P/E

-0.27

EPS (TTM)

-$6.21

Next earnings

Nov 11, 2026

No multiple

Valuation

Recommended · Earnings yield

Price used

$1.86

Earnings yield

Unavailable

Reported earnings

10-year Treasury benchmark: 4.96%

USD · Financial statements through 2026-06-30 · EPS source period not supplied

A positive earnings figure and a usable price are needed to calculate earnings yield.

Method, dates & sources

Earnings per share divided by the price used, compared with the 10-year Treasury rate.

Price timestamp: Sep 21, 2026, 8:00 PM UTC
Financial statement period: Financial statements through 2026-06-30 · EPS source period not supplied
Data refreshed: Sep 22, 2026, 9:55 AM UTC · provider

Why this method?

The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Is there enough operating history to anchor a DCF? Only 3 years of public or statement history are available, so multiples are more decision-useful than a DCF here.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

1Y Price: -88.48%FCF (TTM): 9.85%

What changed

The stock fell 88.48% over the last year. Free cash flow grew 9.85% over the trailing twelve months.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

This read is wrong if revenue rolls over, margins compress again, or free cash flow keeps deteriorating. In that case the selloff would be catching up with weaker business quality rather than just a lower multiple.

Performance

Return analysis

Company profile

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies.

CEOA. Rachel Leheny

SectorHealthcare

IndustryBiotechnology

Employees15

IPO dateJun 14, 2023

https://www.calcimedica.com

Market multiples

Forward P/E—

EV/EBITDA-3,521.14

Enterprise value$98.92B

Stock splits

Aug 31, 2026↓ Reverse

Every 5 shares became 1

-80%

Mar 20, 2023↓ Reverse

Every 14 shares became 1

-93%

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROEN/A

Analyst consensus

RatingBuy

Target price$266.00▲14201.08%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 11, 2026

Q4 FY26 · EPS est -$1.28 · Revenue est —

View

NASDAQ · CALC

CalciMedica, Inc.

Healthcare · Biotechnology

$1.86▼ 3.13% ($0.06)at close

As of 4:00 PM ET

52-week

$1.86$36.00

Market cap

$5.86M

P/E

-0.27

EPS (TTM)

-$6.21

Next earnings

Nov 11, 2026

No multiple

Valuation

Recommended · Earnings yield

Price used

$1.86

Earnings yield

Unavailable

Reported earnings

10-year Treasury benchmark: 4.96%

USD · Financial statements through 2026-06-30 · EPS source period not supplied

A positive earnings figure and a usable price are needed to calculate earnings yield.

Method, dates & sources

Earnings per share divided by the price used, compared with the 10-year Treasury rate.

Price timestamp: Sep 21, 2026, 8:00 PM UTC
Financial statement period: Financial statements through 2026-06-30 · EPS source period not supplied
Data refreshed: Sep 22, 2026, 9:55 AM UTC · provider

Why this method?

The company is still too young and does not have a stable, multi-year FCFF base. Use EV/Revenue multiples and comparable transactions instead of a DCF.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Is there enough operating history to anchor a DCF? Only 3 years of public or statement history are available, so multiples are more decision-useful than a DCF here.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

1Y Price: -88.48%FCF (TTM): 9.85%

What changed

The stock fell 88.48% over the last year. Free cash flow grew 9.85% over the trailing twelve months.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

Performance

Return analysis

Company profile

CEOA. Rachel Leheny

SectorHealthcare

IndustryBiotechnology

Employees15

IPO dateJun 14, 2023

https://www.calcimedica.com

Market multiples

Forward P/E—

EV/EBITDA-3,521.14

Enterprise value$98.92B

Stock splits

Aug 31, 2026↓ Reverse

Every 5 shares became 1

-80%

Mar 20, 2023↓ Reverse

Every 14 shares became 1

-93%

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROEN/A

Analyst consensus

RatingBuy

Target price$266.00▲14201.08%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 11, 2026

Q4 FY26 · EPS est -$1.28 · Revenue est —

View